Consumers top reaction to DTC ads? Seek more info: survey

Share this article:
Consumers’ No. 1 reaction after seeing a DTC prescription drug ad is to seek more information about advertised treatments, according to a new survey released today. The findings are part of the 10th Annual National Survey on Consumer Reaction to DTC Pharmaceutical Advertising, which polled 1,500 US adult consumers in March and was conducted by the Rodale-published magazines Prevention, Men’s Health and Women’s Health with assistance from the FDA’s DDMAC. “Health information seeking for prescription drugs, is an ongoing process …so it doesn’t mean that people see an ad, run to the doctor’s office and everything’s over,” Cary Silvers, director of consumer and advertising trends at Rodale, told MM&M. “We are seeing consumer information seeking before they go to the doctor’s office, while they are getting the drug filled at drug store and we are seeing information seeking in 75% of people after they’ve gotten a new drug.” Other highlights from the survey included: *Most consumers (68%) claim they know a lot about their medical condition or illness, the benefits of the prescription medicines they take (67%), and the risks (59%). These numbers compare to only 2% of consumers who claim they are knowledgeable about investing, the survey said. *Even after a prescription is filled, the majority of surveyed consumers (75%) are still looking for information about their medications. Twenty-nine percent of these consumers find themselves stopping to read/watch an advertisement. *Only a small amount of surveyed consumers (8%) are stimulated to ask their doctor for a specific medication after seeing a DTC ad. *More consumers agree or somewhat agree (73%) that DTC ads allow people to be more involved with their healthcare. *A little more than half of consumers (56%) are currently taking a prescription drug. Ten years ago, 47% of consumers were. *Among the 36% of consumers who remember seeing any disease awareness ad, half (52%) say they have either talked with their doctor, a friend or family member or searched for additional information online.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...